Pakistan's former stalwarts on Sunday lashed out at the Pakistan Cricket Board (PCB) for acting in haste in removing Sarfaraz Ahmed as captain in all three formats of the game.
Most of the former captains and players termed the removal of Sarfaraz on Friday as unjust. Not surprisingly, the head coach and chief selector Misbah-ul-Haq and bowling coach Waqar Younis were also targeted and blamed for engineering the ouster of Sarfaraz.
Sarafarz has been replaced as Test captain by Azhar Ali while Babar Azam will take over in T20s. A decision on the ODI captaincy will be finalised in due course.
The wicketkeeper-batsman is also unlikely to be part of the touring Pakistan T20 or Test squad to Australia later this month.
Batting great Javed Miandad said since Sarfaraz had gained considerable experience as a captain in the last two years, he should have been given time to regain his form instead of just sacking him.
"Azhar's appointment as Test captain is okay but if the Board wanted to appoint Babar as white-ball captain, they should have first groomed him as I fear the burden of T20 captaincy will affect his batting," Miandad said.
Former Test batsman and ex-head coach and chief selector Mohsin Khan said, "He (Sarfaraz) took Pakistan to number one in T20 cricket and he is a fighter. This is a decision taken in haste and it could also affect the career of Babar."
Former captain Rashid Latif minced no words in stating that the Board had erred by making Babar captain of the T20 side.
"He is a selfish player and we have seen this in international cricket and now in the national T20 championship. Sarfaraz is not a selfish captain and sacrificed his position many times for the team. He did not deserve this treatment," he said.
Former skipper Moin Khan said he was shocked at the way the Board had treated Sarfaraz.
"He (Sarfaraz) has shown himself to be a fine captain and yes he was struggling a bit for form but when a senior player is under pressure you have to encourage and back him, not dump him like this," Moin said.
He noted that Misbah and Waqar had never been fond of Sarfaraz and with them in charge, this sacking was expected.
Former Test pacer Aaqib Javed also criticised the Board for taking a strange decision.
"I don't know from where these decisions are coming but they make no sense at all to me. Sarfaraz should have been relieved as Test captain but the Board should have given him some time as captain of white-ball cricket."
Another former captain Ramiz Raja, however, felt that the Board had taken a brave decision to appoint Babar Azam as T20 captain and said people defending Sarfaraz should accept his poor form in recent months as skipper.
"We were struggling in Test cricket, we did not reach semifinals of the World Cup. We lost to a Sri Lankan 'B' team in T20 cricket and his own form is on a decline. I think the Board acted properly by investing in a young player in the white-ball formats. If Babar develops into a good leader he can also become Test captain," he said.
Former fast bowler Shoaib Akhtar said Sarfaraz only had himself to blame for his ouster.
"I have been saying for a while now that he needs to be a brave captain and player. He has not been physically fit and he lacked leadership qualities," Akhtar said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.